Dr Humna Riaz, Dr Wajiha Arshad, Dr Muhammad Bilal Bhatti
Objective: The assessment and evaluation of L-Methyl folate efficacy in the combine form along with the escitalopram in comparison to the escitalopram monotherapy in the depression. Material and Methods: The duration of this study was from January, 2020 to June, 2020 in 6 months at Services Hospital Lahore. The number of patients was 260 which were having Major Depression’s primary diagnosis along with score above fourteen on depression (Hamilton rating scale) i.e., HAM-D & they were selected in this study of Randomized Controlled Trial. The patients were classified in two groups & then group-A was given ten milligram (Escitalopram) in addition to placebo while group B was given ten milligram (Escitalopram) in addition to L-Methyl folate in the form of a dose of 15 mg. Group-A and Group-B were assessed again after 1 month & the scores of HAM-D were measured. Results: In the total number of 260 patients, the response was there in 70.8% i.e., 184 & 29.2% i.e., 76 never responded to the treatment. The patients were 82 at 63.1% which have shown response to treatment but 48 patients at 36.9 % never responded and these patients were total 130 which were treated along with SSRI. In total 130 patients which were treated with escitalopram & L-Methyl folate, 28 at 21.5% never responded and 102 at 78.5% showed response to treatment. With a confidence interval of 95%, the P-value was observed as (0.006) which showed that primary difference of both interventions was statistically significant. Conclusion: In the findings of this study a combination of L-Methyl folate & SSRI in depression may prove to be more efficient as compared to the Escitalopram monotherapy. Keywords: Escitalopram Monotherapy, Hamilton Rating Scale, Escitalopram, L-Methyl Folate.